NASDAQ:INFI Infinity Pharmaceuticals (INFI) Stock Price, News & Analysis → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free INFI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.01▼$0.1352-Week Range N/AVolume2.48 million shsAverage Volume2.58 million shsMarket Capitalization$726,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Infinity Pharmaceuticals alerts: Email Address Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. About Infinity Pharmaceuticals Stock (NASDAQ:INFI)Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.Read More Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. INFI Stock News HeadlinesMay 7, 2024 | finance.yahoo.comSeaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive AppointmentsMay 2, 2024 | finance.yahoo.comQ1 2024 Glaukos Corp Earnings CallMay 13, 2024 | Paradigm Press (Ad)Dems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.March 16, 2024 | nytimes.comPi Day: How One Irrational Number Made Us ModernMarch 14, 2024 | msn.comBiotech bankruptcies hit a record despite sector’s recoveryMarch 13, 2024 | benzinga.comDavid Schnell's Net WorthMarch 11, 2024 | msn.comMemphis Police issue alert after mother and two children abductedJanuary 31, 2024 | finance.yahoo.comStryker Expands Prophecy® Surgical Planning System to Include the New Footprint™, Offering Surgeons a Comprehensive View of the Foot and AnkleMay 13, 2024 | Paradigm Press (Ad)Dems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.December 22, 2023 | seekingalpha.comAGNPF Algernon Pharmaceuticals Inc.December 12, 2023 | morningstar.comInfinity Pharmaceuticals Inc INFIQDecember 1, 2023 | seekingalpha.comINFIQ Infinity Pharmaceuticals, Inc.October 16, 2023 | businesswire.comINFI DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 16 Deadline in Securities ...October 16, 2023 | barrons.comFINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $500,000 to Contact the FirmOctober 15, 2023 | stockhouse.comInfinity Ongoing Deadline AlertOctober 14, 2023 | bloomberg.comDeadline Alert: Bronstein, Gewirtz & Grossman LLC Announces that Infinity Pharmaceuticals, Inc. (INFI) Investors Have OpportuniOctober 10, 2023 | finance.yahoo.comInfinity Pharmaceuticals, Inc. (INFIQ)October 9, 2023 | barrons.comBronstein, Gewirtz & Grossman LLC Notifies Infinity Pharmaceuticals, Inc. (INFI) Investors of Class Action and to Actively Participate!October 2, 2023 | bizjournals.comGutted Cambridge biotech declares bankruptcy after failed merger, layoffsOctober 1, 2023 | markets.businessinsider.comInfinity Investor Shareholder AlertSeptember 29, 2023 | msn.comInfinity Pharmaceuticals reportedly files for Chapter 11September 22, 2023 | finanznachrichten.deFaron Pharmaceuticals Oy: Faron Pharmaceuticals Announces Board ChangesSeptember 18, 2023 | stockhouse.comINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmSeptember 16, 2023 | prnewswire.comINFINITY DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Infinity To Contact Him Directly To Discuss Their OptionsSeptember 16, 2023 | markets.businessinsider.comROSEN, A TOP RANKED LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INFISeptember 15, 2023 | stockhouse.comINVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmSeptember 14, 2023 | stockhouse.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmSee More Headlines Receive INFI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Infinity Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2021Today5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:INFI CUSIP45665G30 CIK1113148 Webwww.infi.com Phone(617) 453-1000Fax617-453-1001Employees30Year Founded2000Profitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-44,370,000.00 Net Margins-1,593.93% Pretax Margin-1,593.93% Return on EquityN/A Return on Assets-113.02% Debt Debt-to-Equity RatioN/A Current Ratio1.65 Quick Ratio1.65 Sales & Book Value Annual Sales$2.59 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.21) per share Price / BookN/AMiscellaneous Outstanding Shares90,760,000Free Float81,857,000Market Cap$726,000.00 OptionableOptionable Beta1.63 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Lawrence E. Bloch J.D. (Age 57)M.D., Treasurer Comp: $513.61kMr. Seth A. Tasker J.D. (Age 44)CEO, Sr. VP, Gen. Counsel & Sec. Key CompetitorsBellerophon TherapeuticsNASDAQ:BLPHHistogenNASDAQ:HSTOComera Life SciencesNASDAQ:CMRAEvofem BiosciencesNASDAQ:EVFMSciSparcNASDAQ:SPRCView All CompetitorsInsidersAdelene Q PerkinsSold 410,196 sharesTotal: $28,713.72 ($0.07/share) INFI Stock Analysis - Frequently Asked Questions How were Infinity Pharmaceuticals' earnings last quarter? Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) posted its earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.02. The biotechnology company had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.45 million. During the same period last year, the business earned ($0.16) earnings per share. What is Adelene Q. Perkins' approval rating as Infinity Pharmaceuticals' CEO? 10 employees have rated Infinity Pharmaceuticals Chief Executive Officer Adelene Q. Perkins on Glassdoor.com. Adelene Q. Perkins has an approval rating of 100% among the company's employees. This puts Adelene Q. Perkins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Infinity Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Novavax (NVAX) and Celldex Therapeutics (CLDX). This page (NASDAQ:INFI) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceThe A.I. story nobody is telling you (Read ASAP)TradeSmithElon to Transform U.S. Economy? Porter & CompanyBill Clinton Backing Biden Replacement???The Freeport SocietyUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Infinity Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.